Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 7/20 | 0.66 |
| ▸ | PDE4A | P27815 | 3/20 | 0.66 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.66 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.66 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2887769 | 0.95 | PDE4D (0.63) | PDE4DPDE4APDE4BPDE4CPKM | |
| SCHEMBL2889838 | 0.87 | PDE4D (0.56) | PDE4DPDE4APDE4BPDE4CPKM | |
| SCHEMBL30084822 | 0.87 | PDE4D (0.56) | PDE4DPDE4APDE4BPDE4CPKM | |
| SCHEMBL2882309 | 0.86 | PDE4D (0.67) | PDE4DPDE4APDE4BPDE4CPKM | |
| SCHEMBL2887510 | 0.82 | PDE4D (0.69) | PDE4DPDE4APDE4BPDE4CPKM | |
| SCHEMBL30084839 | 0.81 | NPC1 (0.59) | PDE4DPDE4APDE4BPDE4CPKM | |
| SCHEMBL2889399 | 0.81 | PDE4D (0.64) | PDE4DPDE4APDE4BPDE4CPKM | |
| SCHEMBL2887760 | 0.81 | NPC1 (0.59) | PDE4DPDE4APDE4BPDE4CPKM | |
| SCHEMBL30084831 | 0.80 | PDE4D (0.80) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL7334292 | 0.80 | PDE4D (1.00) | PDE4DPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240316015-A1 | COMPOSITION AND METHOD FOR TREATING TUMORS | NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) | 2024-09-26 | — | — | US | disclosed |
| EP-4282413-A1 | COMPOSITION AND METHOD FOR TREATING TUMORS | NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) | 2023-11-29 | — | — | EP | disclosed |
| US-20230338345-A1 | DRUG COMBINATION AND USE THEREOF | NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) | 2023-10-26 | — | — | US | disclosed |
| EP-4140480-A1 | DRUG COMBINATION AND USE THEREOF | NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) | 2023-03-01 | — | — | EP | disclosed |
| WO-2022156727-A1 | COMPOSITION AND METHOD FOR TREATING TUMORS | 浙江养生堂天然药物研究所有限公司 | 2022-07-28 | — | — | WO | disclosed |
| WO-2021213455-A1 | DRUG COMBINATION AND USE THEREOF | 浙江养生堂天然药物研究所有限公司 (CN) | 2021-10-28 | — | — | WO | disclosed |
| US-7776893-B2 | Use of PDE4 inhibitors for the treatment of diabetes mellitus | NYCOMED GMBH (DE) | 2010-08-17 | — | — | US | disclosed |
| EP-0706513-B1 | FLUOROALKOXY-SUBSTITUTED BENZAMIDES AND THEIR USE AS CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS | BYK GULDEN LOMBERG CHEM FAB (DE) | 2002-05-15 | — | — | EP | disclosed |
| US-5712298-A | Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1998-01-27 | — | — | US | disclosed |
| EP-0706513-A1 | FLUOROALKOXY-SUBSTITUTED BENZAMIDES AND THEIR USE AS CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1996-04-17 | — | — | EP | disclosed |
| WO-1995001338-A1 | FLUOROALKOXY-SUBSTITUTED BENZAMIDES AND THEIR USE AS CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1995-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240316015-A1 | COMPOSITION AND METHOD FOR TREATING TUMORS | PDE4B, PDE4A, PDE4C | PDE4D 4/4885PDE4A 2/4885PDE4B 1/4885 |
| US-20230338345-A1 | DRUG COMBINATION AND USE THEREOF | PDE4B, PDE4A, ADH4 | PDE4D 15/4885PDE4A 2/4885PDE4B 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.